Abstract
In 1991, Reverse Transcriptase – Polymerase Chain Reaction (RT-PCR) was introduced to assess the expression of Tyrosinase in the peripheral blood of melanoma patients, in order to identify the presence of Circulating Melanoma Cells. To date, hundreds of studies, some of which are reviewed here, were performed to assess the clinical value of tyrosinase expression alone, and/or, in addition to other molecular markers. Unfortunately no consensus on the utility of tyrosinase detection exists. In this paper, we underline the presence of too many variables that may interfere with the detection of circulating melanoma cells: from withdrawal and RNA extraction, to Reverse Transcriptase – Polymerase Chain Reaction and the assays used for the analysis of amplification products.
Keywords: Tyrosinase, melanoma, RT-PCR, peripheral blood
Current Cancer Drug Targets
Title: Tyrosinase Expression as a Molecular Marker for Investigating the Presence of Circulating Tumor Cells in Melanoma Patients
Volume: 10 Issue: 5
Author(s): A. Gradilone, E. Cigna, A.M. Agliano and L. Frati
Affiliation:
Keywords: Tyrosinase, melanoma, RT-PCR, peripheral blood
Abstract: In 1991, Reverse Transcriptase – Polymerase Chain Reaction (RT-PCR) was introduced to assess the expression of Tyrosinase in the peripheral blood of melanoma patients, in order to identify the presence of Circulating Melanoma Cells. To date, hundreds of studies, some of which are reviewed here, were performed to assess the clinical value of tyrosinase expression alone, and/or, in addition to other molecular markers. Unfortunately no consensus on the utility of tyrosinase detection exists. In this paper, we underline the presence of too many variables that may interfere with the detection of circulating melanoma cells: from withdrawal and RNA extraction, to Reverse Transcriptase – Polymerase Chain Reaction and the assays used for the analysis of amplification products.
Export Options
About this article
Cite this article as:
Gradilone A., Cigna E., Agliano A.M. and Frati L., Tyrosinase Expression as a Molecular Marker for Investigating the Presence of Circulating Tumor Cells in Melanoma Patients, Current Cancer Drug Targets 2010; 10 (5) . https://dx.doi.org/10.2174/156800910791517136
DOI https://dx.doi.org/10.2174/156800910791517136 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tamoxifen in the Treatment of Hepatocellular Carcinoma: 5-Year Results of the CLIP-1 Multicentre Randomised Controlled Trial
Current Pharmaceutical Design Editorial [Hot Topic: Anti-Cancer Drugs Executive Editor: Elke Bergmann-Leitner]
Current Pharmaceutical Design DNA Methylation: An Epigenetic Insight into Type 2 Diabetes Mellitus
Current Pharmaceutical Design Recent Development in [1,4]Benzodiazepines as Potent Anticancer Agents: A Review
Mini-Reviews in Medicinal Chemistry Redox-inactive Analogue of Tocotrienol as a Potential Anti-cancer Agent
Anti-Cancer Agents in Medicinal Chemistry Characterization and Management of Cutaneous Side Effects Related to the Immunosuppressive Treatment in Solid Organ Recipients
Current Drug Targets Affective Temperaments and Mood Disorders: A Review of Current Knowledge
Current Psychiatry Reviews Is There Anybody in There? On The Mechanisms of Wall Crossing of Cell Penetrating Peptides
Current Protein & Peptide Science Benzimidazole Derivatives as Potential Anticancer Agents
Mini-Reviews in Medicinal Chemistry From French Paradox to Cancer Treatment: Anti-cancer Activities and Mechanisms of Resveratrol
Anti-Cancer Agents in Medicinal Chemistry Caring for HIV-Infected Patients in the ICU in The Highly Active Antiretroviral Therapy Era
Current HIV Research Perspectives of Engineered Marine Derived Polymers for Biomedical Nanoparticles
Current Pharmaceutical Design Perspectives on Sesquiterpene Lactones in Inflammation and Cancer
Current Drug Targets The Endothelin Axis as Therapeutic Target in Human Malignancies: Present and Future
Current Pharmaceutical Design Potential of Nanocarriers in Genetic Immunization
Recent Patents on Drug Delivery & Formulation Colorectal Carcinogensis and Suppression of Tumor Development by Inhibition of Enzymes and Molecular Targets
Current Enzyme Inhibition Delivery of Peptidic Gonadotropin Releasing Hormone Antagonists
Current Drug Delivery Current Perspective of Natural Alkaloid Carbazole and its Derivatives as Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy The IGF Axis in Prostate Cancer
Current Pharmaceutical Design